SCHEMBL5016100

SCHEMBL5016100

COc1ccc(CN(C(=O)O)c2cc(-n3cccn3)nc(-c3ccco3)n2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.51
ADORA1 P30542 9/20 0.51
ADORA3 P0DMS8 5/20 0.47
ADORA2B P29275 2/20 0.47
LMNA P02545 5/20 0.43
ALDH1A1 P00352 4/20 0.43
TSHR P16473 3/20 0.43
ALOX15 P16050 3/20 0.43
TP53 P04637 3/20 0.42
MAPK1 P28482 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 6/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
F2 P00734 2/20 0.41
F12 P00748 1/20 0.41
HSD17B10 Q99714 3/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038267 0.86 ADORA2A (0.57) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5026222 0.84 ADORA2A (0.52) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5016138 0.82 ADORA2A (0.52) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5016301 0.80 ADORA2A (0.67) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL6038256 0.79 ADORA2A (0.55) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5024948 0.78 ADORA2A (0.57) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL8287491 0.78 ADORA2A (0.63) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5017747 0.78 ADORA2A (0.65) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5022237 0.77 ADORA2A (0.54) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL5016173 0.77 ADORA2A (0.55) ADORA2AADORA1ADORA3ADORA2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
JP-2007514003-A 2007-05-31 JP claimed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP claimed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.